Curevac suffers setback in patent dispute
The biotech company Curevac has suffered a setback in the patent dispute with its rival Biontech. In a ruling in Munich, the Federal Patent Court declared a patent claimed by Curevac null and void. The patent on vaccines, which the European Patent Office had granted to Curevac, was not valid in Germany, said the presiding judge Walter Schramm.
The Mainz-based company Biontech made a name for itself with its Covid-19 vaccine, which the company and its partner Pfizer have sold billions of units of. The Tübingen-based competitor Curevac accuses Biontech of having infringed several patents. Biontech, in turn, is investigating whether Curevac's property rights are valid at all.
Read also:
- Why there is still no EU funding for green Saar steel
- 3 billion Saar Fund is unconstitutional
- Abrupt end to e-car subsidies
- The chemical industry has little confidence
The patent dispute between Biontech and Curevac has escalated, with Biontech now investigating the validity of Curevac's property rights following Curevac's setback in the dispute. Despite its rival's legal setback, Curevac still accuses Biontech of infringing several of its patents.
Source: www.ntv.de
